Optimal dose, timing and ratio of blood products in massive transfusion: Results from a systematic review

Optimal dose, timing and ratio to red blood cells (RBC) of blood component therapy (fresh frozen plasma [FFP], platelets, cryoprecipitate or fibrinogen concentrate) to reduce morbidity and mortality in critically bleeding patients requiring massive transfusion is unknown. We performed a systematic review for randomised controlled trials (RCT) in MEDLINE, The Cochrane Library, Embase, CINAHL, PubMed and the Transfusion Evidence Library using multiple clinical trials registries was undertaken to 21st February 2017.

Source: Transfusion Medicine Reviews - July 6, 2017 Category: Hematology Authors: Zoe K McQuilten, Gemma Crighton, Susan Brunskill, Jessica K Morison, Tania H Richter, Neil Waters, Michael F Murphy, Erica M Wood Source Type: research